JP2005534614A - アルツハイマー病治療のための置換アミノカルボキサミド - Google Patents

アルツハイマー病治療のための置換アミノカルボキサミド Download PDF

Info

Publication number
JP2005534614A
JP2005534614A JP2003558035A JP2003558035A JP2005534614A JP 2005534614 A JP2005534614 A JP 2005534614A JP 2003558035 A JP2003558035 A JP 2003558035A JP 2003558035 A JP2003558035 A JP 2003558035A JP 2005534614 A JP2005534614 A JP 2005534614A
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
aryl
groups
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003558035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005534614A5 (https=
Inventor
ジャゴジンスカ、バーバラ
ワルペホスキー、マーサ、エイ．
Original Assignee
イーラン ファーマスーティカルズ、インコーポレイテッド
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーラン ファーマスーティカルズ、インコーポレイテッド, ファルマシア・アンド・アップジョン・カンパニー・エルエルシー filed Critical イーラン ファーマスーティカルズ、インコーポレイテッド
Publication of JP2005534614A publication Critical patent/JP2005534614A/ja
Publication of JP2005534614A5 publication Critical patent/JP2005534614A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003558035A 2002-01-04 2003-01-06 アルツハイマー病治療のための置換アミノカルボキサミド Pending JP2005534614A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34531602P 2002-01-04 2002-01-04
US35041902P 2002-01-18 2002-01-18
PCT/US2003/000326 WO2003057721A2 (en) 2002-01-04 2003-01-06 Substituted amino carboxamides for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2005534614A true JP2005534614A (ja) 2005-11-17
JP2005534614A5 JP2005534614A5 (https=) 2006-03-16

Family

ID=26994342

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003558035A Pending JP2005534614A (ja) 2002-01-04 2003-01-06 アルツハイマー病治療のための置換アミノカルボキサミド

Country Status (8)

Country Link
US (1) US6962934B2 (https=)
EP (1) EP1458745A2 (https=)
JP (1) JP2005534614A (https=)
AU (1) AU2003206413A1 (https=)
BR (1) BR0306724A (https=)
CA (1) CA2472617A1 (https=)
MX (1) MXPA04006575A (https=)
WO (1) WO2003057721A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509988A (ja) * 2003-10-30 2007-04-19 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病治療のためのヒドロキシプロピルアミド
JP2007516207A (ja) * 2003-06-30 2007-06-21 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病の治療のためのＮ−アルキルフェニルカルボキサミドβ−セクレターゼ阻害剤

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1581510A4 (en) * 2002-11-22 2006-08-30 Bristol Myers Squibb Co 1-ARYL-2-HYDROXYETHYLAMIDEALS CALIUM CHANNEL OPENER
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
CA2548849A1 (en) 2003-12-19 2005-07-21 Merck & Co., Inc. Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
JP2007522129A (ja) * 2004-01-21 2007-08-09 エラン ファーマシューティカルズ，インコーポレイテッド アスパラギン酸プロテアーゼ阻害薬を用いるアミロイドーシスの処置方法
AU2005236063A1 (en) 2004-04-20 2005-11-03 Merck & Co., Inc. 2, 4, 6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease
WO2005103020A1 (en) 2004-04-20 2005-11-03 Merck & Co., Inc. 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005113582A1 (en) * 2004-05-22 2005-12-01 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease
CA2570995A1 (en) * 2004-06-15 2006-01-05 Merck & Co., Inc. Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
CA2603404A1 (en) * 2005-03-30 2006-10-05 Boehringer Ingelheim International Gmbh Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture
KR20080015079A (ko) 2005-04-08 2008-02-18 코멘티스, 인코포레이티드 베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법
EP1915339A1 (de) * 2005-08-11 2008-04-30 Boehringer Ingelheim International GmbH Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung
WO2007017510A2 (de) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Isophthalsäurediamide zur behandlung der alzheimer erkrankung
CA2618019A1 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for the treatment of alzheimer's disease
US20100144681A1 (en) * 2005-08-11 2010-06-10 Klaus Fuchs Compounds for the treatment of alzheimer's disease
WO2007061670A1 (en) 2005-11-21 2007-05-31 Amgen Inc. Beta-secretase modulators and methods of use
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
US7838676B2 (en) 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
US8163909B2 (en) 2007-05-25 2012-04-24 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
CA2687608C (en) 2007-05-25 2013-07-02 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
CA2687750C (en) 2007-07-06 2016-10-18 Boehringer Ingelheim International Gmbh Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
US7803809B2 (en) 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
CA2736130C (en) * 2008-09-11 2014-01-14 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
US9296698B2 (en) 2009-11-23 2016-03-29 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
EP2504330A1 (en) 2009-11-23 2012-10-03 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
AU2011207679B2 (en) 2010-01-19 2013-10-10 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
MX2012010657A (es) 2010-03-15 2013-02-07 Amgen Inc Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico.
EP2547685A1 (en) 2010-03-15 2013-01-23 Amgen Inc. Spiro-tetracyclic ring compounds as beta - secretase modulators
EP2673279A1 (en) 2011-02-07 2013-12-18 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08500081A (ja) * 1992-06-26 1996-01-09 メルク エンド カンパニー インコーポレーテッド ファルネシル蛋白質トランスフェラーゼの阻害剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362912A (en) 1989-05-23 1994-11-08 Abbott Laboratories Process for the preparation of a substituted diaminodiol
US5552558A (en) 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
EP1302468B1 (en) 1992-12-29 2008-12-17 Abbott Laboratories Processes and intermediates for manufacturing retroviral protease inhibiting compounds
US5942400A (en) 1995-06-07 1999-08-24 Elan Pharmaceuticals, Inc. Assays for detecting β-secretase
WO2000006559A1 (en) * 1998-07-30 2000-02-10 Warner-Lambert Company Reduced dipeptide analogues as calcium channel antagonists
EP1192177A1 (en) * 1999-06-15 2002-04-03 Elan Pharmaceuticals, Inc. Statine-derived tetrapeptide inhibitors of beta-secretase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08500081A (ja) * 1992-06-26 1996-01-09 メルク エンド カンパニー インコーポレーテッド ファルネシル蛋白質トランスフェラーゼの阻害剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6009054971, Ｎｉｚａｌ Ｓ． Ｃｈａｎｄｒａｋｕｍａｒ ｅｔ ａｌ．, "Ｐｒｅｐａｒａｔｉｏｎ ａｎｄ Ｏｐｉｏｉｄ Ａｃｔｉｖｉｔｙ ｏｆ Ａｎａｌｏｇｓ ｏｆ ｔｈｅ Ａｎａｌｇｅｓｉｃ Ｄｉｐｅｐｔｉｄｅ ２，６−Ｄｉｍｅｔｈｙｌ−Ｌ−ｔｙｒｏｓｙｌ−Ｎ−（３−ｐｈ", Ｊ． Ｍｅｄ． Ｃｈｅｍ．, 1992, Ｖｏｌ．３５， Ｎｏ．２, ｐ．２２３−２３３ *
JPN6009054972, Ｙａｅｋｏ Ｋｏｎｄａ ｅｔ ａｌ．, "Ａｌｋａｌｏｉｄ ｆｒｏｍ Ｔｈｅｒｍｏａｃｔｉｎｏｍｙｃｅｓ Ｓｐｅｃｉｅｓ", Ｃｈｅｍ． Ｐｈａｒｍ． Ｂｕｌｌ．, 1976, Ｖｏｌ．２４， Ｎｏ．１, ｐ．９２−９６ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007516207A (ja) * 2003-06-30 2007-06-21 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病の治療のためのＮ−アルキルフェニルカルボキサミドβ−セクレターゼ阻害剤
JP2007509988A (ja) * 2003-10-30 2007-04-19 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病治療のためのヒドロキシプロピルアミド

Also Published As

Publication number Publication date
US6962934B2 (en) 2005-11-08
EP1458745A2 (en) 2004-09-22
CA2472617A1 (en) 2003-07-17
WO2003057721A2 (en) 2003-07-17
US20030166580A1 (en) 2003-09-04
WO2003057721A3 (en) 2004-03-25
AU2003206413A1 (en) 2003-07-24
AU2003206413A8 (en) 2003-07-24
MXPA04006575A (es) 2004-10-04
BR0306724A (pt) 2006-04-11

Similar Documents

Publication Publication Date Title
JP2005534614A (ja) アルツハイマー病治療のための置換アミノカルボキサミド
US7358264B2 (en) Statine derivatives for the treatment of Alzheimer's disease
JP4278511B2 (ja) Ｎ−（３−アミノ−２−ヒドロキシ−プロピル）置換アルキルアミド化合物
JP2006524255A (ja) ベンズアミド２−ヒドロキシ−３−ジアミノアルカン
JP2005514330A (ja) アルツハイマー病治療のための置換アミン
JP2005538162A (ja) １，３−ジアミノ−２−ヒドロキシプロパンプロドラッグ誘導体
JP2005504022A (ja) アルツハイマー病治療のためのジアミンジオール
JP2006524258A (ja) フェナシル２−ヒドロキシ−３−ジアミノアルカン
JP2005505506A (ja) アルツハイマー病の治療に有用な大環状分子
JP2004502665A (ja) アルツハイマー病を治療する化合物
JP2005500319A (ja) アルツハイマー病の治療に有用なβ−ヒドロキシアミン誘導体
US20090291970A1 (en) Substituted Aminoethers for the Treatment of Alzheimer's Disease
JP2004532894A (ja) アルツハイマー病を治療するためのアミンジオール
JP2004534064A (ja) アルツハイマー病の治療に有用な大環状分子
JP2005505517A (ja) アルツハイマー病を治療するためのアミンジオール
US7763646B2 (en) Compounds for the treatment of alzheimer's disease
JP2005536448A (ja) アミン１，２−及び１，３−ジオール化合物、及びアルツハイマー病を治療するためのその使用
JP2007509988A (ja) アルツハイマー病治療のためのヒドロキシプロピルアミド

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091023

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100514